{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:47:54Z","timestamp":1767494874874,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00277-023-05140-6","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T03:03:51Z","timestamp":1678935831000},"page":"1111-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8905-2039","authenticated-orcid":false,"given":"Ethan A.","family":"Burns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar Gentille","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim N.","family":"Muhsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humaira","family":"Sarfraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Chi Andrew","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hang Anthony","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpan S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo W.","family":"Tremont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Teh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Ravi Kiran","family":"Pingali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"issue":"3","key":"5140_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/neuonc\/1.3.205","volume":"1","author":"FG Davis","year":"1999","unstructured":"Davis FG, McCarthy BJ, Berger MS (1999) Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; surveillance, epidemiology, and end results; and national cancer data base. Neuro Oncol 1(3):205\u2013211. https:\/\/doi.org\/10.1093\/neuonc\/1.3.205","journal-title":"Neuro Oncol"},{"issue":"11","key":"5140_CR2","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/1097-0142(19881201)62:11<2461::aid-cncr2820621135>3.0.co;2-m","volume":"62","author":"NL Eby","year":"1988","unstructured":"Eby NL, Grufferman S, Flannelly CM, Schold SC Jr, Vogel FS, Burger PC (1988) Increasing incidence of primary brain lymphoma in the US. Cancer 62(11):2461\u20132465. https:\/\/doi.org\/10.1002\/1097-0142(19881201)62:11%3c2461::aid-cncr2820621135%3e3.0.co;2-m","journal-title":"Cancer"},{"key":"5140_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.canep.2009.09.006","volume":"33","author":"XC Wu","year":"2009","unstructured":"Wu XC, Andrews P, Chen V, Groves F (2009) Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians\/Pacific Islanders in the United States: anatomic site and histology differences. Cancer Epidemiol 33:337\u2013346. https:\/\/doi.org\/10.1016\/j.canep.2009.09.006","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"5140_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjh.14073","volume":"174","author":"MS Shiels","year":"2016","unstructured":"Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L et al (2016) Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 174(3):417\u2013424. https:\/\/doi.org\/10.1111\/bjh.14073","journal-title":"Br J Haematol"},{"issue":"4","key":"5140_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.4143\/crt.2014.085","volume":"47","author":"SH Shin","year":"2015","unstructured":"Shin SH, Jung KW, Ha J, Lee SH, Won YJ, Yoo H (2015) Population-based incidence and survival for primary central nervous system lymphoma in Korea, 1999\u20132009. Cancer Res Treat 47(4):569\u2013574. https:\/\/doi.org\/10.4143\/crt.2014.085","journal-title":"Cancer Res Treat"},{"key":"5140_CR6","volume-title":"The next four decades, the older population in the United States: 2010 to 2050. Current population reports","author":"GK Vincent","year":"2010","unstructured":"Vincent GK, Velkoff VA (2010) The next four decades, the older population in the United States: 2010 to 2050. Current population reports.\u00a0https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2010\/demo\/p25-1138.pdf. Last accessed: February 7, 2023."},{"key":"5140_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000495284","volume":"141","author":"T Siegal","year":"2019","unstructured":"Siegal T, Bairey O (2019) Primary CNS lymphoma in the elderly: the challenge. Acta Haematol 141:138\u2013145. https:\/\/doi.org\/10.1159\/000495284","journal-title":"Acta Haematol"},{"issue":"10","key":"5140_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Intergroupe GOELAMS\u2013ANOCEF and the LOC Network for CNS Lymphoma, et al (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37(10):823\u2013833. https:\/\/doi.org\/10.1200\/JCO.18.00306","journal-title":"J Clin Oncol"},{"issue":"6","key":"5140_CR9","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","volume":"2","author":"A Omuro","year":"2015","unstructured":"Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V et al (2015) Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2(6):e251\u2013e259. https:\/\/doi.org\/10.1016\/S2352-3026(15)00074-5","journal-title":"Lancet Haematol"},{"issue":"4","key":"5140_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/leu.2016.334","volume":"31","author":"K Fritsch","year":"2017","unstructured":"Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, M\u00f6hle R et al (2017) High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia 31(4):846\u2013852. https:\/\/doi.org\/10.1038\/leu.2016.334","journal-title":"Leukemia"},{"issue":"4","key":"5140_CR11","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3324\/haematol.2014.108472","volume":"100","author":"EJ Pulczynski","year":"2015","unstructured":"Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Foss\u00e5 A, Eriksson M, Nordstr\u00f8m M, \u00d8stenstad B, Fluge \u00d8, Lepp\u00e4 S, Fiirgaard B, Bersvendsen H, Fagerli UM (2015) Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica 100(4):534\u2013540. https:\/\/doi.org\/10.3324\/haematol.2014.108472","journal-title":"Haematologica"},{"issue":"9","key":"5140_CR12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0b013e318266fcb2","volume":"79","author":"P Roth","year":"2012","unstructured":"Roth P, Martus P, Kiewe P, M\u00f6hle R, Klasen H, Rauch M, R\u00f6th A, Kaun S, Thiel E, Korfel A, Weller M (2012) Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 79(9):890\u2013896. https:\/\/doi.org\/10.1212\/WNL.0b013e318266fcb2","journal-title":"Neurology"},{"issue":"5","key":"5140_CR13","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/s2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, International Extranodal Lymphoma Study Group (IELSG) et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3(5):e217\u2013e227. https:\/\/doi.org\/10.1016\/s2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"key":"5140_CR14","unstructured":"Texas Health and Human Services. About the Texas cancer registry.\u00a0https:\/\/www.dshs.texas.gov\/tcr\/about.aspx. Accessed 4 Apr\u00a02022"},{"key":"5140_CR15","unstructured":"Texas Demographic Center (2018) Projections of the population of Texas and counties in Texas by age, sex, and race\/ ethnicity for 2010-2050.\u00a0https:\/\/demographics.texas.gov\/Data\/TPEPP\/Projections\/Methodology.pdf. Accessed 25 Feb\u00a02022"},{"key":"5140_CR16","volume-title":"Aging in Texas","author":"Texas Demographic Center","year":"2016","unstructured":"Texas Demographic Center (2016) Aging in Texas.\u00a0https:\/\/demographics.texas.gov\/resources\/publications\/2016\/2016_06_07_aging.pdf\u00a0Last accessed 25 February 2022"},{"key":"5140_CR17","unstructured":"United States Census Bureau. https:\/\/www.census.gov\/quickfacts\/TX. Accessed 25 Feb\u00a02022"},{"key":"5140_CR18","volume-title":"Demographics of Texas and the aging of the population","author":"Texas Demographic Center","year":"2018","unstructured":"Texas Demographic Center (2018) Demographics of Texas and the aging of the population.\u00a0https:\/\/demographics.texas.gov\/Resources\/Presentations\/OSD\/2018\/2018_02_22_JLLSeniorsHousingOutlook.pdf\u00a0Last accessed 25 February 2022."},{"key":"5140_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life tables (with discussion). J Roy Stat Soc B 34:187\u2013220","journal-title":"J Roy Stat Soc B"},{"key":"5140_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"issue":"7","key":"5140_CR21","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/cncr.10851","volume":"95","author":"JE Olson","year":"2002","unstructured":"Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D et al (2002) The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95(7):1504\u20131510. https:\/\/doi.org\/10.1002\/cncr.10851","journal-title":"Cancer"},{"issue":"5","key":"5140_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","volume":"20","author":"JS Mendez","year":"2018","unstructured":"Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS et al (2018) The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol 20(5):687\u2013694. https:\/\/doi.org\/10.1093\/neuonc\/nox187","journal-title":"Neuro Oncol"},{"issue":"9","key":"5140_CR23","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/bjc.2011.357","volume":"105","author":"JL Villano","year":"2011","unstructured":"Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105(9):1414\u20131418. https:\/\/doi.org\/10.1038\/bjc.2011.357","journal-title":"Br J Cancer"},{"issue":"10","key":"5140_CR24","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","volume":"94","author":"C Houillier","year":"2020","unstructured":"Houillier C, Soussain C, Ghesqui\u00e8res H, Soubeyran P, Chinot O, Taillandier L et al (2020) Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 94(10):e1027\u2013e1039. https:\/\/doi.org\/10.1212\/WNL.0000000000008900","journal-title":"Neurology"},{"issue":"1","key":"5140_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12885-022-09315-8","volume":"22","author":"I Puhakka","year":"2022","unstructured":"Puhakka I, Kuitunen H, J\u00e4k\u00e4l\u00e4 P, Sonkaj\u00e4rvi E, Turpeenniemi-Hujanen T, R\u00f6nk\u00e4 A et al (2022) Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis. BMC Cancer 22(1):236. https:\/\/doi.org\/10.1186\/s12885-022-09315-8","journal-title":"BMC Cancer"},{"issue":"8","key":"5140_CR26","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/leu.2017.128","volume":"31","author":"M van der Meulen","year":"2017","unstructured":"van der Meulen M, Dinmohamed AG, Visser O, Doorduijn JK, Bromberg JEC (2017) Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989\u20132015. Leukemia 31(8):1822\u20131825. https:\/\/doi.org\/10.1038\/leu.2017.128","journal-title":"Leukemia"},{"issue":"1","key":"5140_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/ejh.12980","volume":"100","author":"S Eloranta","year":"2018","unstructured":"Eloranta S, Branvall E, Celsing F, Papworth K, Ljungqvist M, Enblad G et al (2018) Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000\u20132013. Eur J Haematol 100(1):61\u201368. https:\/\/doi.org\/10.1111\/ejh.12980","journal-title":"Eur J Haematol"},{"issue":"suppl_7","key":"5140_CR28","doi-asserted-by":"publisher","first-page":"vii6","DOI":"10.1093\/neuonc\/noy090","volume":"20","author":"H Gittleman","year":"2018","unstructured":"Gittleman H, Boscia A, Ostrom QT, Truitt G, Fritz Y, Kruchko C et al (2018) Survivorship in adults with malignant brain and other central nervous system tumor from 2000\u20132014. Neuro Oncol 20(suppl_7):vii6\u2013vii16. https:\/\/doi.org\/10.1093\/neuonc\/noy090","journal-title":"Neuro Oncol"},{"key":"5140_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/aol-20-30","volume":"5","author":"N Martinez-Calle","year":"2021","unstructured":"Martinez-Calle N, Isbell LK, Cwynarski K, Schorb E (2021) Treatment of elderly patients with primary CNS lymphoma. Ann Lymphoma 5:2. https:\/\/doi.org\/10.21037\/aol-20-30","journal-title":"Ann Lymphoma"},{"issue":"9","key":"5140_CR30","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ et al (2015) R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125(9):1403\u20131410. https:\/\/doi.org\/10.1182\/blood-2014-10-604561","journal-title":"Blood"},{"issue":"25","key":"5140_CR31","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B et al (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31(25):3061\u20133068. https:\/\/doi.org\/10.1200\/JCO.2012.46.9957","journal-title":"J Clin Oncol"},{"issue":"31","key":"5140_CR32","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B et al (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31(31):3971\u20133979. https:\/\/doi.org\/10.1200\/JCO.2013.50.4910","journal-title":"J Clin Oncol"},{"issue":"4","key":"5140_CR33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","volume":"10","author":"LM DeAngelis","year":"1992","unstructured":"DeAngelis LM, Yahalom J, Thaler HT, Kher U (1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10(4):635\u2013643. https:\/\/doi.org\/10.1200\/JCO.1992.10.4.635","journal-title":"J Clin Oncol"},{"issue":"2","key":"5140_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3171\/jns.1994.81.2.0188","volume":"81","author":"J Glass","year":"1994","unstructured":"Glass J, Gruber ML, Cher L, Hochberg FH (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81(2):188\u2013195. https:\/\/doi.org\/10.3171\/jns.1994.81.2.0188","journal-title":"J Neurosurg"},{"issue":"7","key":"5140_CR35","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"AJM Ferreri","year":"2022","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, IELSG32 study investigators et al (2022) Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia 36(7):1870\u20131878. https:\/\/doi.org\/10.1038\/s41375-022-01582-5","journal-title":"Leukemia"},{"issue":"3","key":"5140_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11060-020-03547-z","volume":"148","author":"R Velasco","year":"2020","unstructured":"Velasco R, Mercadal S, Vidal N, Ala\u00f1\u00e1 M, Barcel\u00f3 MI, Ib\u00e1\u00f1ez-Juli\u00e1 MJ et al (2020) Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. J Neurooncol 148(3):545\u2013554. https:\/\/doi.org\/10.1007\/s11060-020-03547-z","journal-title":"J Neurooncol"},{"issue":"19","key":"5140_CR37","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1002\/cncr.25363","volume":"116","author":"DE Ney","year":"2010","unstructured":"Ney DE, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE (2010) Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer 116(19):4605\u20134612. https:\/\/doi.org\/10.1002\/cncr.25363","journal-title":"Cancer"},{"issue":"6","key":"5140_CR38","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/cncr.22907","volume":"110","author":"KS Panageas","year":"2007","unstructured":"Panageas KS, Elkin EB, Ben-Porat L, Deangelis LM, Abrey LE (2007) Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 110(6):1338\u20131344. https:\/\/doi.org\/10.1002\/cncr.22907","journal-title":"Cancer"},{"issue":"17","key":"5140_CR39","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.3390\/cancers13174268","volume":"13","author":"E Schorb","year":"2021","unstructured":"Schorb E, Isbell LK, Illerhaus G, Ihorst G, Meerpohl JJ, Grummich K et al (2021) Treatment regimens for immunocompetent elderly patients with primary central nervous system lymphoma: a scoping review. Cancers (Basel) 13(17):4268. https:\/\/doi.org\/10.3390\/cancers13174268","journal-title":"Cancers (Basel)"},{"issue":"8","key":"5140_CR40","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/bmt.2017.23","volume":"52","author":"E Schorb","year":"2017","unstructured":"Schorb E, Fox CP, Fritsch K, Isbell L, Neubauer A, Tzalavras A et al (2017) High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transplant 52(8):1113\u20131119. https:\/\/doi.org\/10.1038\/bmt.2017.23","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5140_CR41","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12885-019-5473-z","volume":"19","author":"E Schorb","year":"2019","unstructured":"Schorb E, Finke J, Ihorst G, Kasenda B, Fricker H, Illerhaus G (2019) Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. BMC Cancer 19(1):287. https:\/\/doi.org\/10.1186\/s12885-019-5473-z","journal-title":"BMC Cancer"},{"issue":"1","key":"5140_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noac196","volume":"25","author":"K Hoang-Xuan","year":"2023","unstructured":"Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R et al (2023) European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol 25(1):37\u201353. https:\/\/doi.org\/10.1093\/neuonc\/noac196","journal-title":"Neuro Oncol"},{"key":"5140_CR43","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12885-016-2311-4","volume":"16","author":"E Schorb","year":"2016","unstructured":"Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B et al (2016) High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma\u2013a randomized phase III trial (MATRix). BMC Cancer 16:282. https:\/\/doi.org\/10.1186\/s12885-016-2311-4","journal-title":"BMC Cancer"},{"issue":"11","key":"5140_CR44","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Ros\u00e9e P, International Extranodal Lymphoma Study Group (IELSG) et al (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol 4(11):e510\u2013e523. https:\/\/doi.org\/10.1016\/S2352-3026(17)30174-6","journal-title":"Lancet Haematol"},{"issue":"5","key":"5140_CR45","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.16451","volume":"189","author":"E Schorb","year":"2020","unstructured":"Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T et al (2020) Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice. Br J Haematol 189(5):879\u2013887. https:\/\/doi.org\/10.1111\/bjh.16451","journal-title":"Br J Haematol"},{"issue":"2","key":"5140_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/annonc\/mdn628","volume":"20","author":"G Illerhaus","year":"2009","unstructured":"Illerhaus G, Marks R, M\u00fcller F, Ihorst G, Feuerhake F, Deckert M et al (2009) High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 20(2):319\u2013325. https:\/\/doi.org\/10.1093\/annonc\/mdn628","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05140-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05140-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05140-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T14:18:57Z","timestamp":1729088337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05140-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5140"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05140-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing or financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Since this was a retrospective database study with data provided by the Texas Cancer Registry, informed consent was not obtained by individual subjects. All data was released as an aggregate of de-identified data by the Texas Cancer Registry following approval of a written protocol in order to protect patient confidentiality.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"EAB declares that he has no conflict of interest. CGS declares that he has no conflict of interest. SM declares that he has no conflict of interest. CG declares that he has no conflict of interest. INM declares that he has no conflict of interest. HS declares that she has no conflict of interest. CCAH declares that he has no conflict of interest. CHAT declares that he has no conflict of interest. SSS declares that he has no conflict of interest. IWT declares that he has no conflict of interest. BT declares that he has no conflicts of interest. SG declares that he has no conflict of interest. SRP declares that he has no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}